CONMED Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CONMED Corporation (NYSE: CNMD) on May 27, 2026. The filing details the entry into a material definitive agreement regarding the company's credit facilities.
Key Financial Metrics and Debt Structure
- New Debt Facility: Established a Term A-2 Loan Facility with an aggregate principal amount of $450 million.
- Availability: Funds are available for a single drawing on or prior to June 14, 2026.
- Maturity: The facility matures on June 10, 2030, aligning with existing revolving and term loan facilities.
- Interest Rates: Margins are based on the consolidated senior secured leverage ratio. Initial margins are 1.75% per annum for adjusted term SOFR borrowings and 0.75% per annum for base rate borrowings.
- Collateral: Obligations are secured by the same assets and rights as the existing Credit Agreement and guaranteed by the same subsidiaries.
Material Changes and Purpose
The primary purpose of the First Omnibus Amendment is to secure incremental senior secured delayed draw term loans. The proceeds from the $450 million facility are designated to:
- Repurchase a portion of CONMED's outstanding 2.25% Convertible Senior Notes due 2026.
- Pay fees and expenses associated with the repurchase and the amendment.
This filing amends the Eighth Amended and Restated Credit Agreement dated June 10, 2025.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, revenue outlook, or management commentary regarding operational performance. The primary risk disclosed relates to the creation of a direct financial obligation and the associated debt service requirements under the new Term A-2 Loan Facility.
Investor Verification Checklist
- Verify the exact amount of the 2.25% Convertible Senior Notes due 2026 repurchased using the new facility proceeds.
- Review the consolidated senior secured leverage ratio to confirm the applicable interest rate margin tier.
- Examine the full text of the First Omnibus Amendment (Exhibit 10.1) for specific covenants and prepayment terms.
- Confirm the impact of the new debt on the company's overall liquidity and debt-to-equity ratio.